证券代码：600750 证券简称：江中药业 公告编号：2025-068 江中药业股份有限公司 关于公司高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）董事会于近日收到总经理肖文 斌先生、财务总监周违莉女士的辞职报告。因工作调整，肖文斌先生申请辞去公 司总经理职务，周违莉女士申请辞去公司财务总监职务，辞职报告书自送达董事 会之日起生效。肖文斌先生、周违莉女士辞职后仍在公司担任其他职务。 经公司第十届董事会提名委员会 2025 年第三次会议、第十届董事会审计委 员会 2025 年第七次会议和第十届董事会第十一次会议审议通过，董事会聘任徐 永前先生为公司总经理；聘任罗小荣先生、李海棠先生、杨琰先生为公司副总经 理；聘任黄炎伟先生为公司财务总监，任期自董事会审议通过之日起至公司本届 董事会届满为止。 一、高级管理人员离任情况 上述人员的简历详见附件。 | | | | 原定任期 | | 是否继续在上 | | 是否存在 未履行完 | | --- | --- | ...

国浩律师（上海）事务所 法律意见书 2025 年第二次临时股东大会的法律意见书 致：江中药业股份有限公司 江中药业股份有限公司（以下简称"公司"）2025 年第二次临时股东大会（以 下简称"本次股东大会"）现场会议定于 2025 年 12 月 29 日下午 14:50 在江西省 南昌市新建区招贤 1 路江中药谷会议室召开，国浩律师（上海）事务所（以下 简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华人民共和 国证券法》、《中华人民共和国公司法》和《江中药业股份有限公司章程》（以 下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和股东大会表决程序、表决结果等发表法律意见。法律意 见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本法律意见书作为公司本次股东大会的必备文件公告，并依 法对本所出具的法律意见承 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-065 江中药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 12 月 29 日 (二)股东大会召开的地点：江西省南昌市新建区招贤 1 路江中药谷会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 211 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 309,451,079 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 48.7360 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长刘为权先生主持，采取现场投票与网络投票相结合的表决方式。 表决方式符合《公司法》及《公司章程》的有关规定。 (五)公司董事、监事 ...

江中药业股份有限公司 第十届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"或"江中药业"）第十届董事会 第十一次会议于 2025 年 12 月 29 日在公司会议室以现场结合视频方式召开，会 议通知于 2025 年 12 月 24 日以书面形式发出，会议应到董事 11 人，实到董事 11 人。公司高级管理人员列席。本次会议召集召开符合《公司法》和《公司章 程》的有关规定。 会议由公司董事长刘为权先生主持，经与会董事充分研究和讨论，审议通 过以下议案： 一、关于聘任公司总经理的议案 表决情况：10 票同意，0 票反对，0 票弃权，1 票回避，通过本议案。 根据《公司法》《公司章程》等相关规定，结合公司经营管理需要，经公司 董事长提名、公司董事会提名委员会资格审查，董事会聘任徐永前先生为公司 总经理，任期与公司第十届董事会任期一致。 董事徐永前对本议案履行了回避表决程序。 证券代码：600750 证券简称：江中药业 公告编号：2025-067 具体内容详见公 ...

Group 1 - Jiangzhong Pharmaceutical (SH 600750) announced the convening of its 11th meeting of the 10th Board of Directors on December 29, 2025, to discuss the appointment of a new general manager [1] - For the first half of 2025, Jiangzhong Pharmaceutical's revenue composition was as follows: pharmaceutical industry accounted for 99.64%, liquor industry 0.25%, and other businesses 0.11% [1] - As of the report date, Jiangzhong Pharmaceutical's market capitalization was 15 billion yuan [1] Group 2 - A new type of chip has been developed in China, which bypasses the restrictions on lithography machines and supports AI training and embodied intelligence, capable of mass production using mature processes of 28 nanometers and above [1]

近年来，中医药滋补养生市场持续扩容。其中，六味地黄类产品作为滋阴补肾的经典品类，市场需求潜 力巨大。与此同时，传统剂型正加速向更便捷、更适口的方向创新，膏滋、口服液等新剂型日益受到当 代快节奏生活人群的青睐。华润江中敏锐洞察这一趋势，将传承千年的经典名方与现代剂型创新相结 合，为滋阴补肾市场带来一款易于服用、方便携带、高效吸收的膏滋新品，满足现代消费者对高效、便 捷、品质滋补的新需求。 12月25日，华润江中旗下六味地黄膏在京东健康首发上线，消费者即日起登录京东APP搜索"江中六味 地黄膏"即可咨询与购买，开启轻松、便捷的滋补调理新体验。 作为国民信赖的健康品牌，华润江中始于1969年，是一家集医药研发、生产与销售于一体的国有大型企 业，旗下"江中"品牌价值超466亿元，已连续22年入选中国500最具价值品牌。其位于南昌的江中药谷制 造基地，是国家级绿色工厂与智能制造的典范。2023年，华润江中牵头获批"经典名方现代中药创制全 国重点实验室"，依托4个国家级及8个省部级研发平台，构建了从药材源头到产品出厂的全链条质量管 控体系，为六味地黄膏等产品的卓越品质保驾护航。 本次新品发布是双方深度合作的又一重要里程碑 ...

Group 1 - The core product launched by China Resources Jiangzhong is a new formulation of the classic "Liuwei Dihuang Wan," transitioning from pill to paste form, designed for modern fast-paced lifestyles [1] - The traditional Chinese medicine market for kidney tonics is projected to reach 48.73 billion yuan in 2024, with a year-on-year growth of 9.2%, indicating a significant consumer trend towards health products that are efficient and convenient [1] - The new product features a portable design with independent packaging, enhancing convenience for users while also focusing on taste by incorporating honey for a sweet and slightly sour flavor [1] Group 2 - A representative from China Resources Jiangzhong emphasized that this innovation reflects the company's commitment to providing convenient health solutions and its role as a leader in the inheritance and innovation of traditional Chinese medicine [2] - Alibaba Health stated its role as a launch platform for new specialty drugs, aiming to provide consumers with easy access to health products, with many regions offering same-day or next-day delivery for the new product [2]

Group 1 - The core viewpoint of the articles highlights the growing market for kidney-tonifying traditional Chinese medicine (TCM) products, driven by changing consumer habits and the need for convenient health solutions in fast-paced urban lifestyles [1][2] - The market size for kidney-tonifying TCM products is projected to reach 48.73 billion yuan in 2024, reflecting a year-on-year growth of 9.2%, and accounting for 12.6% of the overall TCM market [1] - The introduction of the "Liuwedi Huang Gao" by China Resources Jiangzhong represents an innovation in dosage form, transitioning from traditional pills to a convenient paste format, catering to the needs of modern professionals [1][2] Group 2 - The new product features a portable, individually packaged design that emphasizes convenience and taste, incorporating high-quality honey for a pleasant flavor experience [2] - The launch of "Liuwedi Huang Gao" on Alibaba Health aims to provide consumers with easy access to health products, with same-day or next-day delivery options available in various regions [2] - The initiative reflects the company's commitment to integrating traditional Chinese medicine into modern lifestyles while fulfilling the health needs of the public [2]

Investment Rating - The report initiates coverage with a "Buy" rating for Jiangzhong Pharmaceutical, indicating a potential upside of 36% based on a target market value of 214 billion yuan compared to the current market value of 157 billion yuan [7][8]. Core Insights - Jiangzhong Pharmaceutical is positioned as a leader in gastrointestinal health, with a diversified business model encompassing OTC, prescription drugs, and health consumer products. The company has successfully built a strong brand presence with its well-known trademarks "Jiangzhong" and "Chuyuan" [5][16]. - The company has a robust product portfolio, including major products in the OTC market such as the 1 billion yuan "Jiangzhong Digestive Tablets" and the 500 million yuan "Lactobacillus Tablets" [7][36]. - The financial outlook is positive, with projected net profits for 2025-2027 expected to grow at compound annual growth rates of 8.3%, 10.0%, and 11.9%, respectively [6][8]. Summary by Sections Company Overview - Jiangzhong Pharmaceutical was established in 1969 and became publicly listed in 1998. The company has undergone significant restructuring and acquisitions, including the purchase of Jisheng Pharmaceutical and Sanghai Pharmaceutical, to enhance its market position [5][16]. - The company has a stable shareholding structure, with China Resources Group as the largest shareholder, which strengthens its operational capabilities and risk management [18][19]. Financial Data and Profit Forecast - The total revenue for 2024 is projected at 4.435 billion yuan, with a slight decline expected in 2025 before a recovery in subsequent years, reaching 5.089 billion yuan by 2027 [6]. - The gross profit margin is expected to remain stable around 65%, with the OTC segment showing a slight increase in profitability due to product mix optimization [26]. Investment Highlights - The company is focusing on expanding its OTC market presence by leveraging its strong brand and developing new product categories. The gastrointestinal product line is expected to maintain stable growth, while the health consumer products segment is anticipated to benefit from demographic trends such as aging populations [7][32]. - Jiangzhong Pharmaceutical's prescription drug segment is also expected to grow as the company continues to enhance its product offerings through acquisitions and strategic partnerships [7][32]. Market Position and Competitive Landscape - The company has maintained a leading market share in the OTC segment, particularly with its flagship product, the Jiangzhong Digestive Tablets, which ranked second in sales among digestive system medications in urban pharmacies [38][44]. - The competitive landscape for gastrointestinal products is fragmented, but Jiangzhong Pharmaceutical's brand strength allows it to maintain a dominant position [42][44].

江中药业股份有限公司 2025 年第二次临时股东大会会议材料 江中药业股份有限公司 2025 年第二次临时股东大会会议材料 南 昌 二〇二五年十二月 1 江中药业股份有限公司 2025 年第二次临时股东大会会议材料 议案目录 | 议案一：关于变更公司名称及证券简称、变更注册资本、取消监事会 | | | --- | --- | | 并修订《公司章程》的议案 | 7 | | 议案二：关于修订公司《股东会议事规则》的议案 12 | | | 议案三：关于修订公司《董事会议事规则》的议案 21 | | | 议案四：关于修订公司《关联交易管理办法》的议案 27 | | | 议案五：关于修订公司《董事会提案管理细则》的议案 36 | | | 议案六：关于修订公司《独立董事制度》的议案 39 | | | 议案七：关于增补公司第十届董事会非独立董事的议案 46 | | | 议案八：关于增补公司第十届董事会独立董事的议案 49 | | 2 江中药业股份有限公司 2025 年第二次临时股东大会会议材料 江中药业股份有限公司 股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效 率，根据《中华人民共和国公司法》 ...